Menu Search
Equities

Mersana Therapeutics Inc

0M4:MUN

Mersana Therapeutics Inc

Actions
  • Price (EUR)1.92
  • Today's Change-0.154 / -7.43%
  • Shares traded--
  • 1 Year change+33.45%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Mersana Therapeutics Inc grew revenues 38.65% from 26.58m to 36.86m while net income improved from a loss of 204.21m to a smaller loss of 171.67m.
Gross margin--
Net profit margin-214.19%
Operating margin-229.50%
Return on assets-34.51%
Return on equity-280.29%
Return on investment-50.38%
More ▼

Cash flow in USDView more

In 2023, Mersana Therapeutics Inc increased its cash reserves by 35.31%, or 45.68m. Cash Flow from Investing totalled 119.88m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 168.88m for operations while cash generated from financing totalled 94.68m.
Cash flow per share-0.5988
Price/Cash flow per share--
Book value per share0.0085
Tangible book value per share0.0085
More ▼

Balance sheet in USDView more

Mersana Therapeutics Inc has a Debt to Total Capital ratio of 96.04%, a higher figure than the previous year's 48.19%.
Current ratio2.35
Quick ratio--
Total debt/total equity24.27
Total debt/total capital0.9604
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.